Federal backing accelerates U.S. bioindustrial pilot plants, closing manufacturing gap

The real bottleneck in U.S. biomanufacturing is no longer the lab bench. It is the missing middle between a promising strain, a working process and a plant that can actually run at scale, and BioMADE says that gap has forced American companies to look overseas for the facilities they need.

That is why the latest federal backing matters. BioMADE says the United States has a “foundational gap” in domestic pilot- and intermediate-scale bioindustrial manufacturing infrastructure, and Congress provided an initial down payment in 2023 to help build it out through BioMADE. The Department of Defense has described the effort as a $400 million network of bioindustrial pilot plants meant to advance domestic biomanufacturing, strengthen national security and support a broader bioeconomy.

The push sharpened on April 29, when BioMADE announced $21.4 million across 14 new projects in bioindustrial manufacturing, with support from the Department of War and the National Science Foundation. One of the clearest food-relevant awards is a cell-cultured chocolate project led by the University of California, Davis and California Cultured, aimed at lowering production costs for high-quality chocolate by using cacao plant cell culture. That kind of work is not just about novelty. It is about getting unit economics down to where a process can survive the jump from research to real production.

BioMADE’s pilot plant network, launched in 2023, is now spreading regionally. Minnesota was announced in June 2023 with support of up to $100 million from Governor Tim Walz and the Minnesota Legislature. California followed with a pilot-scale facility backed by at least $80 million in investment and Defense Department funding. BioMADE announced a third site in Iowa on August 15, 2025; the Iowa facility broke ground on November 14, 2025, will total 15,000 square feet and is scheduled to open in 2027.

The policy backdrop is increasingly explicit. The National Security Commission on Emerging Biotechnology delivered its final report to Congress on April 8, 2025, calling for Congress to authorize and fund the Energy Department and the Commerce Department to build a nationwide network of manufacturing facilities for precommercial bioindustrial scale-up. It warned that dependence on China for critical supply-chain elements is a national-security vulnerability.

For precision fermentation and adjacent protein platforms, the value of this buildout is practical and immediate. BioMADE says its multi-user facilities offer industrial fermentation equipment and downstream processing services, and its technology program targets Manufacturing Readiness Levels 4 through 7, exactly the zone where many startups stall. If these pilot plants work as intended, more dairy proteins, egg alternatives and specialty ingredients can move from expensive pilot runs to repeatable production, and the companies that benefit first will be the ones closest to commercial launch.